NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Health

Medical Devices

Clinical Trials

Other Health

National Institute for Health and Care Excellence

More Like This

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions

PR Newswire associated0

The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

PR Newswire associated0

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia